Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.
Xiao WangSilka D FreieslebenLuisa-Sophie SchneiderLukas PreisJosef PrillerEike J SpruthSlawek AltensteinAnja SchneiderKlaus FliessbachJens WiltfangNiels HansenFrank JessenAyda RostamzadehEmrah DüzelWenzel GlanzEnise I IncesoyKatharina BuergerDaniel JanowitzMichael EwersMatthias BrendelBoris-Stephan RauchmannStefan J TeipelIngo KilimannDoreen GoerssChristoph LaskeMatthias H J MunkAnnika SpottkeNina Roy-KluthMichael T HenekaFrederic BrosseronMichael WagnerSteffen WolfsgruberAlfredo RamirezLuca KleineidamMelina StarkOliver PetersPublished in: Neurology (2024)
Our findings suggest that CSF neurogranin and BACE1 begin to change in the preclinical stage of AD and they are associated with clinical progression in individuals with SCD.